The Clinical Application Value of RDW, CA153, and MPV in Breast Cancer

Clin Lab. 2021 Feb 1;67(2). doi: 10.7754/Clin.Lab.2020.200507.

Abstract

Background: Early detection of tumors is beneficial to the treatment of patients. Certain indicators in the blood routine, such as red blood cell distribution width (RDW), are considered to be used to assess the patient's condition and prognosis. Mean platelet volume (MPV) is also used to assess the prognosis of patients. Carbohydrate antigen 153 (CA153) is considered to be a more specific antigen marker for breast cancer. The purpose of our study was to explore the diagnostic value of RDW, MPV, and CA153 for breast cancer (BC) and breast hyperplasia (BH).

Methods: The study included 104 breast cancer patients, 100 breast hyperplasia patients, and 100 healthy controls. CA153 was detected by an automatic electrochemical luminescence analyzer (Cobas e601, Roche Diagnostics, Switzerland). The concentration of RDW and MPV in serum was measured by Sysmex XN-10-B3 (Sysmex, Ja¬pan).

Results: Compared with the breast hyperplasia group, the RDW and CA153 of the breast cancer group were increased. The healthy control group, mammary gland hyperplasia group, and breast cancer were positively correlated with RDW and CA153. Logistic regression results show that increasing age, increasing RDW, and increasing CA153 can increase the risk of breast cancer. The area under the ROC (AUC) analysis showed that the combined specificity and sensitivity of the combined application of RDW, MPV, and CA153 for the identification of breast cancer is better than that of a single marker.

Conclusions: The combined application of RDW, MPV, and CA153 can improve the differential diagnosis of breast cancer and breast hyperplasia.

MeSH terms

  • Biomarkers, Tumor
  • Breast Neoplasms* / diagnosis
  • Erythrocyte Indices
  • Female
  • Humans
  • Mean Platelet Volume*
  • Prognosis

Substances

  • Biomarkers, Tumor